


CNS Tumors

by: Rahaf Naser

CNS TUMORS:

- may arise from the cells of the coverings (meningiomas), the brain cells (gliomas, neuronal tumors), or other CNS cell populations (primary CNS lymphoma, germ cell tumors), or they may originate elsewhere in the body (metastases).
- Can involve the brain or spinal cord



EPIDEMIOLOGY:

- INCIDENCE:**
 - Annual incidence of CNS tumors in the U.S →
 - 24 /100,000 for intracranial tumors, 1/3 malignant
 - 1-2/100,000 for intraspinal tumors
- Metastases are more common than primary brain tumors.


Characteristic features of CNS tumors:

- No Premalignant stage: no in situ lesions**
- Metastasis is rare!**
 - Even the most highly malignant gliomas rarely spread outside of the CNS.
 - but the brain is not comparably protected against the spread of distant tumors.

Characteristic features of CNS tumors:

- Growth pattern (infiltrative or not) and tumor location strongly influence the prognosis:**
 - Even low-grade lesions may infiltrate large regions of the brain, leading to serious clinical deficits, inability to be resected, and poor prognosis.
 - The anatomic site of the neoplasm can influence outcome independent of tumor type or grade due to local effects

* The histologic grading of CNS tumors depends on:



Grade 1 lesions

- ↓ (benign)
- low proliferative activity
 - can be cured after surgical resection alone
 - examples:
 - pilocytic astrocytoma
 - Subependymal giant cell astrocytoma
 - Choroid plexus papilloma
 - myxopapillary ependymoma

Grade 2 lesions

- ↓
- low proliferative activity
 - usually infiltrative and often recur
 - Some tend to progress to higher grades
 - examples:
 - astrocytoma, IDH-mutant grade 2
 - Oligodendroglioma, IDH-mutant & 1p/19q-codeleted grade 2

Grade 3 lesions

- ↓
- Clear histologic evidence of malignancy (nuclear atypia and higher proliferative activity (mitosis))
- In most settings, patients receive radiation and/or chemotherapy
- examples:
 - astrocytoma, IDH-mutant grade 3
 - Oligodendroglioma, IDH-mutant & 1p/19q-codeleted grade 3

Grade 4 lesions

- ↓ (high grade)
- Cytologically malignant, mitotically active, rapid proliferation, necrosis-prone neoplasms & microvascular proliferation.
 - associated with rapid pre- and postoperative disease evolution & fatal outcome
 - Widespread infiltration of surrounding tissue and risk of craniospinal dissemination
 - examples:
 - Glioblastoma, IDH-wild type
 - Medulloblastoma
 - Pineoblastoma
 - most embryonal neoplasms

WHO grades of select CNS tumors	
Diffuse astrocytic and oligodendroglial tumors	
Diffuse astrocytoma, IDH-mutant	I
Anaplastic astrocytoma, IDH-mutant	II
Glioblastoma, IDH-wildtype	IV
Glioblastoma, IDH-mutant	IV
Diffuse midline glioma, H3 K27M-mutant	IV
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted	II
Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted	III
Other astrocytic tumors	
Pilocytic astrocytoma	I
Subependymal giant cell astrocytoma	I
Anaplastic astrocytic xanthanastrocytoma	III
Ependymal tumors	
Subependymoma	I
Myxopapillary ependymoma	I
Ependymoma	II
Ependymoma, RELA fusion-positive	II or III
Anaplastic ependymoma	III
Other gliomas	
Anaplastic glioma	III
Choroid glioma of third ventricle	II
Choroid plexus papilloma	I
Anaplastic choroid plexus papilloma	III
Choroid plexus carcinoma	III
Neuronal and mixed neuronal-glioma tumors	
Dysplastic neuroepithelial tumor	I
Ganglioglioma	I
Anaplastic ganglioglioma	III
Dysembryoplastic neuroepithelial tumor	I
Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos)	I
Dermatologic infantile astrocytoma and ganglioglioma	I
Familial gliomatous tumour	I
Central neurocytoma	II
Embryonal neurocytoma	II
Embryonal rhabdomyosarcoma	II
Embryonal sarcoma of the pineal region	II or III
Pineoblastoma	IV
Papillary tumor of the pineal region	II or III
Embryonal tumors	
Medulloblastoma (all subtypes)	IV
Embryonal tumor with multivesicular cysts, C19MC-allele	IV
Medulloepithelioma	IV
Embryonal tumor, NOS	IV
Anaplastic neuroblastoid tumor	IV
CNS embryonal tumor with retinoid features	IV
Tumors of the cranial and paraspinal nerves	
Neurofibroma	I
Plexiform neurofibroma	I
Malignant peripheral nerve sheath tumour (MPNST)	I, III or IV
Meningeal tumors	
Meningeal sarcoma	III
Meningeal sarcoma	III
Anaplastic (malignant) meningioma	III
Mesenchymal, non-meningothelial tumors	
Solitary fibrous tumour / hemangiopericytoma	I, II or III
Hemangioblastoma	I
Tumors of the sellar region	
Craniohypopharyngeal tumour	I
Cranial nerve sheath tumour	I
Pituitary adenoma	I
Spindle cell sarcoma	I

Pediatric CNS tumors:

- 20% of all pediatric tumors.
- Childhood CNS tumors differ from those in adults in:
 - Location:**
 - 2/3 infratentorial in kids (posterior fossa)
 - 2/3 supratentorial in adults (cerebral hemispheres above tentorium)
 - Mutation profile & histologic subtype:**
 - Kids:** medulloblastoma, pilocytic astrocytoma, ependymoma
 - Adults:** glioblastoma, metastases, meningiomas, diffuse gliomas constitute most gliomas in adults (including astrocytomas and oligodendrogliomas)

CLASSIFICATION OF CENTRAL NERVOUS SYSTEM TUMORS

16


Courtesy of Dr. Pieter Wesseling

- For nearly a century, the classification of brain tumors has been done according to their microscopic similarities with what's thought to be their cell of origin (based on the light microscopic appearance, the immunohistochemical expression of proteins, and the electron microscopic assessment of ultrastructural features).
- The 2016 classification breaks with this nearly century-old tradition and incorporates well-established molecular parameters into the classification.

- the classification includes diagnostic categories that depend on **genotype**.
- The 2016 WHO classification implemented the **combined phenotypic-genotypic diagnostics based on histologic features & tumor genetic profile (integrated diagnosis)**.
- The 2016 classification helped **improving treatment protocols and predicting prognosis**.

18

CNS tumors



Gliomas

Genetic alterations in gliomas

Mutations in isocitrate dehydrogenase (IDH) genes

- Observed as **EARLY** event in gliomagenesis
- Seen in **astrocytomas & oligodendrogliomas**
- Gain of function mutation

IDH1 codon 132
 IDH2 codon 172

The most frequent is IDH1 R132H mutation (83-91%) of IDH mutant gliomas

R172K is the most frequent IDH2 mutation

- Can be detected by immunohistochemical

Stains & molecular studies:

- IDH1-R132H immune stain
- IDH sequencing for IDH1 codon 132 & IDH2 codon 172

Gain of function mutation → lead to increased production of 2-hydroxyglutarate (oncometabolite) → interferes with the activity of several enzymes that regulate gene expression → DNA hypermethylation & maintaining the cells in stem cell-like physiological states → self-renewal and tumorigenesis

Whole arm co-deletion of 1p and 19q chromosomal segments

- Diagnostic of oligodendrogliomas in the presence of IDH mutation

& the vast majority of IDH mutant and 1p/19q co-deleted oligodendrogliomas carry **TERT** promoter hotspot mutation.

telomerase stabilization
 Cellular immortalization & proliferation

ATRX and P53 loss of function mutation

- Both occur in IDH mutant astrocytomas

ATRX mutation induces abnormal telomeres maintenance mechanism known as "alternative lengthening of telomeres"


→ ATRX mutation is mutual exclusive with the activating promoter mutation of the TERT gene (1p/19q co-deletion)

→ P53 mutation: enable tumor survival

ATRX → associated with genomic instability
 induces P53 dependent cell death
 → mutation in P53 helps these cells to survive


Gliomas	WHO 2016	Gliomas, Glioneuronal and Neuronal Tumours	WHO 2021
2.1: Diffuse astrocytic and oligodendroglial tumours	2.1.1: Astrocytoma, IDH-mutant 2.1.2: Diffuse astrocytoma, IDH-wild-type 2.1.3: Diffuse astrocytoma, NOS 2.1.4: Anaplastic astrocytoma, IDH-mutant 2.1.5: Anaplastic astrocytoma, NOS 2.1.6: Anaplastic astrocytoma, IDH-wild-type 2.1.7: Anaplastic astrocytoma, NOS 2.1.8: Glioblastoma, IDH-wild-type 2.1.8.1: Giant cell glioblastoma 2.1.8.2: Gliosarcoma 2.1.8.3: Epithelial glioblastoma 2.1.9: Glioblastoma, IDH-mutant 2.1.10: Glioblastoma, NOS 2.1.11: Diffuse midline glioma, H3 K27M mutant 2.1.11: Oligodendroglioma, IDH-mutant and 1p/19q co-deleted 2.2: Oligodendroglioma, NOS 2.2.3: Anaplastic oligodendroglioma, IDH-mutant and 1p/19q co-deleted 2.2.4: Anaplastic oligodendroglioma, NOS 2.2.5: Oligodendroglioma, NOS 2.2.6: Anaplastic ependymoma, NOS	2.1: Gliomas, Glioneuronal and Neuronal Tumours 2.1.1: Astrocytoma, IDH-mutant 2.1.2: Oligodendroglioma, IDH-mutant and 1p/19q co-deleted 2.1.3: Glioblastoma, IDH-wild-type 2.1.4: Diffuse astrocytoma, NOS 2.1.5: Anaplastic astrocytoma, NOS 2.1.6: Anaplastic astrocytoma, IDH-wild-type 2.1.7: Anaplastic astrocytoma, NOS 2.1.8: Glioblastoma, IDH-wild-type 2.1.8.1: Giant cell glioblastoma 2.1.8.2: Gliosarcoma 2.1.8.3: Epithelial glioblastoma 2.1.9: Glioblastoma, IDH-mutant 2.1.10: Glioblastoma, NOS 2.1.11: Diffuse midline glioma, H3 K27M mutant 2.1.11: Oligodendroglioma, IDH-mutant and 1p/19q co-deleted 2.2: Oligodendroglioma, NOS 2.2.3: Anaplastic oligodendroglioma, IDH-mutant and 1p/19q co-deleted 2.2.4: Anaplastic oligodendroglioma, NOS 2.2.5: Oligodendroglioma, NOS 2.2.6: Anaplastic ependymoma, NOS	2.1: Gliomas, Glioneuronal and Neuronal Tumours 2.1.1: Astrocytoma, IDH-mutant 2.1.2: Oligodendroglioma, IDH-mutant and 1p/19q co-deleted 2.1.3: Glioblastoma, IDH-wild-type 2.1.4: Diffuse astrocytoma, NOS 2.1.5: Anaplastic astrocytoma, NOS 2.1.6: Anaplastic astrocytoma, IDH-wild-type 2.1.7: Anaplastic astrocytoma, NOS 2.1.8: Glioblastoma, IDH-wild-type 2.1.8.1: Giant cell glioblastoma 2.1.8.2: Gliosarcoma 2.1.8.3: Epithelial glioblastoma 2.1.9: Glioblastoma, IDH-mutant 2.1.10: Glioblastoma, NOS 2.1.11: Diffuse midline glioma, H3 K27M mutant 2.1.11: Oligodendroglioma, IDH-mutant and 1p/19q co-deleted 2.2: Oligodendroglioma, NOS 2.2.3: Anaplastic oligodendroglioma, IDH-mutant and 1p/19q co-deleted 2.2.4: Anaplastic oligodendroglioma, NOS 2.2.5: Oligodendroglioma, NOS 2.2.6: Anaplastic ependymoma, NOS

Glioma, Neuronal and glioneuronal tumors



Adult type diffuse glioma

Astrocytoma



Phenotype

It's a diffusely infiltrating glioma

Genotype

- IDH1 or less frequently IDH2 mutation
- Inactivating mutation in TP53 and/or ATRX
- absence of 1p/19q codeletion

* Age at diagnosis : 40-60

* cerebral hemispheres ± cerebellum, brainstem, or spinal cord

* Presentation :

- Seizures, headaches, and focal neurologic deficits related to the anatomic site of involvement
- Clinically: Static for years or progressive.

The prognosis gets poorer as the grade increases

- On the basis of histologic features astrocytomas, IDH- mutant are stratified into three groups:
 - astrocytomas, IDH- mutant, grade 2, median survival is >10 years.
 - astrocytomas, IDH- mutant grade 3, median survival is 5-10 years
 - astrocytomas, IDH- mutant grade 4, median survival is 3 years.
- **NO grade 1 astrocytoma, IDH- mutant, because by convention grade 1 implies benign behavior and all diffuse gliomas are considered malignant**

Morphology

Macroscopic


Grade 2&3

- Poorly defined infiltrative tumors
- expand and distort the invaded brain
- No discrete mass, infiltration beyond the grossly evident margins

Microscopic

Grade 4


- poorly defined infiltrative tumors
- lacks large area of central necrosis & hemorrhage
- Seen in IDH- wild-type GBM



Grade 2

- * The transition between neoplastic and normal tissue is indistinct.
- * Tumor cells infiltrate normal tissue many centimeters from the main lesion.
 - Hypercellular: (Compared to normal white matter) mild to moderate ↑ in number of glial cell nuclei
 - Cytologic atypias: mild enlarged, elongated or irregular hyperchromatic nuclei NO prominent atypia
- + Fibrillary background made of a network of fine astrocytic cell processes
- NO or rare mitotic activity
- NO necrosis
- NO microvascular proliferation

Grade 3




More densely cellular
More nuclear pleomorphism
Mitotic figures are present
NO necrosis
NO microvascular proliferation

Grade 4

Same as 3
With microvascular proliferation and necrosis

* The presence of homozygous deletion of CDKN2A or CDKN2B → astrocytomas, IDH- mutant, grade 4 (EVEN IF THE HISTOLOGY SUGGESTS A LOWER GRADE).

Glioblastomas



→ Diffuse glioma that is IDH-wildtype and H3 wildtype and has one or more the following features:

- Microvascular proliferation
- Necrosis
- TERT promotor mutation
- EGFR gene amplification
- combined gain of entire chromosome 7 and loss of entire chromosome 10 [+7/-10]

→ The most common malignant glioma (50%) of all primary malignant brain tumors in adults


Age: 6th-8th decades of life

cerebral hemispheres → temporal, parietal, frontal, thalamus, basal ganglia

Radiology: Ring enhancing lesion


- Clinically:
 - rapid progression
 - Seizures, neurocognitive impairment, nausea, vomiting, and headache
 - Rapid infiltration of the corpus callosum with growth to the contralateral hemisphere leading to bilateral symmetrical lesion (butterfly glioma)
- Prognosis: Very Poor even with resection, chemotherapy and radiotherapy the median survival is only about 15-18 months.

Macroscopic



- variation in the gross appearance of the tumor from region to region is characteristic (was called glioblastoma multiforme)
- Some areas are firm and white, others are soft and yellow (due to tissue necrosis), others show regions of cystic degeneration and hemorrhage.

Microscopic





• Similar to astrocytoma, IDH-wild-type, grade 4 with high cellularity, prominent nuclear atypia, thickened nuclei, and mitoses


• Microvascular proliferation: The presence of abnormal vessels with multi-layered 2 layers of nuclei endothelial cells

• The presence of any of the following Molecular features (even in the absence of necrosis or microvascular proliferation) lead to the diagnosis of glioblastoma, IDH-wild-type, grade 4:

- TERT promoter mutation
- EGFR gene amplification
- CDKN2A homozygous deletion



Oligodendroglioma



→ a diffusely infiltrating, slow growing glioma with IDH1 or IDH2 mutation and codeletion of chromosomal arms 1p and 19q.
→ 5-15% of gliomas

Age: 40-50 yrs

mostly cerebral hemispheres mainly frontal or temporal lobes, white matter

- The combination of surgery, chemotherapy, and radiotherapy yields an average survival of:
 - 10-20 years for WHO grade 2
 - 5-10 years for WHO grade 3


NO grade 1 or 4

Grade 3 is more aggressive than grade 2 oligodendrogliomas
When corrected for tumor grade, Oligodendrogliomas (CNS WHO grade 2,5) Have best prognosis among diffuse glial tumors

Macroscopic

Infiltrative tumors with blurring of grey matter-white matter boundary
± gelatinous gray mass, cysts, focal hemorrhage and calcification

Microscopic



- Sheets of regular uniform cells resembling oligodendrocytes
- Spherical nuclei containing finely granular chromatin (salt and pepper)
- The nuclei are surrounded by a clear halo of cytoplasm (fried-egg appearance)
- delicate network of "chicken-wire" like anastomosing capillaries


- Calcification up to 40% of cases

- Mitotic activity usually is absent or low (K167<51)

- NO Spontaneous necrosis

- NO microvascular proliferation

Grade 3




oligodendroglioma, IDH- mutant, & 1p/19q-codeleted WHO grade 3

• Defined as: An IDH-mutant and 1p/19q-codeleted oligodendroglioma with focal or diffuse histological features of anaplasia (i.e. perivascular pathologic microvascular proliferation and/or brisk mitotic activity with or without necrosis)

IDH1m 1p/19q-codeleted Oligodendrogliomas, grades 2-3	Essential diagnostic criteria for oligodendrogliomas, IDH-mutant and 1p/19q-codeleted WHO grade 2	Essential diagnostic criteria for oligodendrogliomas, IDH-mutant and 1p/19q-codeleted WHO grade 3
Diffuse glioma	Diffuse glioma	Diffuse glioma
WHO grade 2 or 3 (WHO grade 2 or 3 necessary condition)	WHO grade 2 or 3 (WHO grade 2 or 3 necessary condition)	WHO grade 3 (WHO grade 3 necessary condition)
Microscopic features: diffuse growth pattern, infiltrative growth, and/or perivascular pseudorosettes	Microscopic features: diffuse growth pattern, infiltrative growth, and/or perivascular pseudorosettes	Microscopic features: diffuse growth pattern, infiltrative growth, and/or perivascular pseudorosettes
Immunohistochemistry: IDH1, IDH2, ATRX, TP53, Ki-67	Immunohistochemistry: IDH1, IDH2, ATRX, TP53, Ki-67	Immunohistochemistry: IDH1, IDH2, ATRX, TP53, Ki-67
Molecular features: IDH1/2 mutation, 1p/19q codeletion	Molecular features: IDH1/2 mutation, 1p/19q codeletion	Molecular features: IDH1/2 mutation, 1p/19q codeletion

Glioma, Neuronal and glioneuronal tumors



Neuronal tumors

Less frequent than gliomas

→ composed of cells with neuronal characteristics and express neuronal markers, such as synaptophysin, neurofilaments, and NeuN

Typically, lower grade lesions & often present with seizures


Gangliogliomas WHO grade 1

- * Children & young adults
- * Slow growing tumor
- * Composed of a mixture of neoplastic ganglion and glial cells
- * Most commonly in the temporal lobe
- * 20-50% have mutations in BRAF gene

Dysembryoplastic neuroepithelial tumor (DNT) WHO grade 1

- Rare
- children and young adults
- Slow growing tumor
- Present with seizure
- Most commonly in the superficial temporal lobe.

Ependymoma



→ glioma, Mostly arise next to the ependyma-lined ventricular system, including the central canal of spinal cord

- Posterior fossa: near the 4th ventricle, accounting for 5-10% of tumors in the first two decades of life
- Supratentorial
- Spinal: the most common location in adults & in patients with NF2

Age:


In first 2 decades of life; near the 4th ventricle (post-fossa) accounting for 5-10% of primary brain tumors in this age group.

In adults, the spinal cord & supratentorial ependymomas occur with almost equal frequency;


* The clinical outcome for completely resected supratentorial and spinal ependymomas is better than for those in posterior fossa.

Grade 2


Grade 3



- Ependymoma, WHO grade 2, microscopic:**
- uniform small cells with round to oval nuclei and granular chromatin in a fibrillary background
 - low cellularity
 - low mitotic count
 - No necrosis or MVP
 - Cilia and microvilli are seen on ultrastructural examination.
- Ependymoma WHO grade 2, Morphology:**
- Tumor cells may form glandlike structures (rosettes) → Rosette formation.
 - Ependymal rosettes: diagnostic hallmark of ependymoma (25%)
 - perivascular pseudorosettes: not specific for ependymoma (seen in glioblastoma and medulloblastoma)
- Ependymal rosettes:**
- tumor cells arranged around central canal or lumen that resemble the embryologic ependymal canal, with long, delicate processes extending into a lumen.
- Perivascular pseudorosettes:**
- tumor cells radially arranged around vessels
 - called "pseudo" because the central structure is not formed by the tumor itself, but instead represents a native, non-neoplastic element.




CNS tumors



Embryonal neoplasms

- * Primitive or undifferentiated
- Small round cell tumor of neuroectodermal origin resembling normal progenitor cells in the developing CNS.
- The most common CNS embryonal tumor is Medulloblastoma accounting for 20% of pediatric brain tumors.
- predominantly in children
- Mainly in cerebellum
- All are highly malignant, WHO grade 4
- Radio sensitive
- The prognosis for untreated patients is dismal
- 5 year survival rate may be as high as 75% with total excision, chemotherapy, and irradiation

Macroscopic





In children (midline) → in adults (lateral)
well circumscribed (often)
* May extend to the cerebellar surface & involve the leptomeninges

COMPLICATIONS :

↳ Medulloblastoma have tendency to spread to the subarachnoid space → dissemination through the CSF

Morphology

- Sheets of small primitive cells (small blue)
- Each cell with little cytoplasm & hyperchromatic elongated or crescent-shaped nuclei
- very cellular
- Mitosis are abundant
- often express neuronal markers such as synaptophysin, expression of glial markers (GFAP) is less common



Primary CNS lymphoma

- The most common CNS neoplasm in immunosuppressed individuals
- In non-immunosuppressed populations, the frequency increases after 60 yrs of age.
- Aggressive disease
- Poor response to chemo. (especially if compared with comparable histology that occur at non-CNS site)

The most common type:

diffuse large B-cell lymphomas

- Primary brain lymphoma -

- Multifocal
- involvement outside of the CNS (in lymph nodes or BM) is rare and late complication
- Relatively well defined as compared with glial neoplasms but not as discrete as metastases

Meningiomas

tumors that arise from meningothelial cells of the arachnoid matter and usually attached to the dura

Age: adults (F > M)

any of the external surfaces of the brain, spinal cord, within the ventricular system, from the stromal arachnoid cells in the choroid plexus

Presentation: most common

headache, Seizures, Weakness (depends on location)

Prognosis determined by

lesion size and location, Surgical accessibility, histologic grade


→ Most meningiomas are easily separable from the underlying brain but some tumors are infiltrative (associated with increased risk of recurrence)

→ Meningiomas express progesterone receptors and may grow more rapidly during pregnancy, only to regress after delivery

Pathogenesis

- The most common cytogenetic abnormality is loss of chromosome 22, especially the long arm (22q). The deletions include the region that harbors the NF2 gene.
- Of sporadic meningiomas, 50% to 60% harbor mutations in the NF2 gene.
- In meningiomas without NF2 mutations, mutations occur in other genes.
- Multiple meningiomas = 8th nerve schwannoma or glial tumor → common in the setting of NF2.

Macroscopic




- rubbery, rounded, or bosselated dural masses that compress underlying brain
- Mostly separable from underlying brain, but some tumors are infiltrative

Meningiomas

>50% of intracranial tumors
Mostly carcinomas

- The most common Primary Sites are lung, breast, Skin (melanoma) kidney and colon (80% of cases)
- Sharply demarcated masses, often at the gray-white matter junction & elicit local edema & reactive gliosis

• The boundary between tumor & brain parenchyma is sharp at the microscopic level with surrounding reactive gliosis.



Meningiomas (WHO grade 1):	MENINGIOMAS, WHO grade 2	MENINGIOMAS, WHO grade 3:
<ul style="list-style-type: none"> well-defined dura-based masses that may compress the brain but do not typically invade it +/- overlying bone extension. Epithelioid cells arranged in whorly (syncytial) pattern +/- psammoma bodies Many histologic subtype, with no prognostic difference, including: <ul style="list-style-type: none"> meningeothelial (most common) → clusters of epithelioid cells with fuzzy or indistinct cell membranes Other patterns include fibrous, transitional, angiomatous, microcystic, lymphoplasmacyte rich, metaplastic, secretory and psammomatous 	<ul style="list-style-type: none"> recurrence and aggressive local growth (may require radiation & surgery) <ol style="list-style-type: none"> 4 to 19 mitoses/10 HPF; or 3 out of 5E: increased cellularity, small cells with a high N:C ratio, prominent nucleoli, patternless growth, or necrosis; or clear cell or chordoid subtypes of meningioma; or unequivocal brain invasion 	<ul style="list-style-type: none"> Rare, highly aggressive, resemble a high-grade sarcoma or carcinoma or melanoma morphologically. <ol style="list-style-type: none"> ≥20 mitoses/10HPF; or Frank anaplasia (sarcoma, carcinoma or melanoma like) or TERT promotor mutation; or Homozygous deletion of CDKN2A/B Papillary; or rhabdoid meningioma.
 <p>Psammoma bodies are concentric rings of calcification deposits</p>		

Familial tumor syndromes

Inherited syndromes caused by mutations in tumor suppressor genes and associated with increased risk of neoplasms
 Tumors of the nervous system make a prominent aspect of some of these syndromes, including:

Tuberous sclerosis

- (Autosomal dominant syndrome)
- 1 in 6000 births

Characterized by

- Cutaneous lesions
 - Angiofibromas
 - localized leathery thickenings (shagreen patches)
 - hypopigmented areas (ash-leaf patches)
 - Subungual fibromas
- development of hamartomas & benign neoplasms involving the brain & other tissues
- Extracerebral lesions:
 - Renal angiomyolipomas
 - Retinal glial hamartomas
 - Pulmonary lymphangioleiomyomatosis & Cardiac rhabdomyomas develop during childhood and adolescence
- Cysts at various sites, including liver, kidneys & Pancreas

Von Hippel-Lindau disease

- (Autosomal dominant disease)
- 1 in 30,000 to 40,000

Associated with

- hemangioblastoma of the CNS - in the cerebellum and retina, brainstem, spinal cord and nerve roots
- Cysts in pancreas, liver and kidney
- Increased risk of renal cell carcinoma
- Pheochromocytomas

CNS hamartomas

- Hamartomas within the CNS take the form of **cortical tubers** and **subependymal nodules**
- Cortical tubers** are epileptogenic, and surgical resection can be beneficial.
- Hamartomas consist of glioneuronal hamartomas and subependymal hamartomas including **subependymal giant cell astrocytomas (SEGA)**

Hemangioblastomas

- highly vascular neoplasms consists of numerous capillary-size or larger thin-walled vessels with intervening neoplastic cells that have vacuolated, lipid-rich cytoplasm.
- The neoplastic stromal cells express **inhibin** (useful diagnostic marker).